Bone Turnover Markers After Standard and Distal Roux-en-Y Gastric Bypass: Results from a Randomized Controlled Trial.

Marius Svanevik, Hilde Risstad, Dag Hofsø, Ingvild K Blom-Høgestøl, Jon A Kristinsson, Rune Sandbu, Milada Cvancarova Småstuen, Per Medbøe Thorsby, Tom Mala, Jøran Hjelmesæth

Journal: Obesity surgery 2020;29(9):2886-2895

PMID: 31065919

Abstract

BACKGROUND

Roux-en-Y gastric bypass is associated with increased risk of bone fractures. Malabsorptive procedures may be associated with secondary hyperparathyroidism and detrimental effects on bone health. We aimed to compare the effects of standard and distal gastric bypass on bone turnover markers 2 years after surgery.

METHODS

Patients with body mass index (BMI) 50-60 kg/m (n = 113) were randomized to standard or distal gastric bypass, 105 patients (95%) completed 2-year follow-up. Serum C-terminal telopeptide of type I collagen (CTX-1), procollagen type I N-propeptide (PINP), and bone-derived alkaline phosphatase (BALP) was measured at baseline and up to 2 years after surgery. ANCOVA and linear mixed models were used to compare groups.

RESULTS

The levels of bone turnover markers increased significantly in both groups, with no statistically significant difference between groups. Two years after standard and distal gastric bypass mean (SD) CTX-1 were 0.81 (0.32) and 0.83 (0.31) μg/L (p = 0.38), mean PINP was 77.6 (23.2) and 77.7 (29.3) μg/L (p = 0.42), and BALP 47.9 (21.9) vs. 50.7 (19.6) μg/L (p = 0.38), respectively. Multiple linear regression analyses showed that PINP and BALP correlated positively (p = 0.01 and p < 0.001) with PTH, but only BALP was significantly higher in patients with secondary hyperparathyroidism (p = 0.001). Type of surgery, vitamin D serum concentrations, and 2-year BMI were all independently associated with PTH levels.

CONCLUSION

A comparable increase in bone turnover markers 2 years after standard and distal gastric bypass was observed. There was a higher prevalence of secondary hyperparathyroidism after distal gastric bypass, but this did not impact bone turnover markers.

TRIAL REGISTRATION

Clinical Trials.gov number NCT00821197.

Address: Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway. [email protected].; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. [email protected].; Department of Gastrointestinal Surgery, Vestfold Hospital Trust, Tønsberg, Norway. [email protected].; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.; Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.; Department of Morbid Obesity and Bariatric Surgery, Oslo University Hospital, Oslo, Norway.; Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Gastrointestinal Surgery, Vestfold Hospital Trust, Tønsberg, Norway.; Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.; Oslo Metropolitan University, Oslo, Norway.; Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.; Department of Morbid Obesity and Bariatric Surgery, Oslo University Hospital, Oslo, Norway.; Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway.; Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.